Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. (2016)

First Author: Porter D
Attributed to:  Glasgow Molecular Pathology (GMP) Node funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(16)00380-9

PubMed Identifier: 27197690

Publication URI: http://europepmc.org/abstract/MED/27197690

Type: Journal Article/Review

Volume: 388

Parent Publication: Lancet (London, England)

Issue: 10041

ISSN: 0140-6736